div class=trans-pagebuttonPage 1button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8ce7e0ea3086c0391f1html5page1jpg target=_blank amp-img class=trans-thumb alt=Page 1: ExtaviJect® 30g device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study src=https:reader038fdokumencomreader038viewer2023032814632dd8ce7e0ea3086c0391f1html5thumbnails1jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 2button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8ce7e0ea3086c0391f1html5page2jpg target=_blank amp-img class=trans-thumb alt=Page 2: ExtaviJect® 30g device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study src=https:reader038fdokumencomreader038viewer2023032814632dd8ce7e0ea3086c0391f1html5thumbnails2jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 3button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8ce7e0ea3086c0391f1html5page3jpg target=_blank amp-img class=trans-thumb alt=Page 3: ExtaviJect® 30g device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study src=https:reader038fdokumencomreader038viewer2023032814632dd8ce7e0ea3086c0391f1html5thumbnails3jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 4button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8ce7e0ea3086c0391f1html5page4jpg target=_blank amp-img class=trans-thumb alt=Page 4: ExtaviJect® 30g device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study src=https:reader038fdokumencomreader038viewer2023032814632dd8ce7e0ea3086c0391f1html5thumbnails4jpg width=142 height=106 layout=responsive amp-imga divdivdiv...